Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPM1D Is a Therapeutic Target in Childhood Neural Tumors

30 Nov 2021

Abstract excerpt

Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17q23.2. PPM1D encodes a serine/threonine phosphatase, WIP1, that is a negative regulator of p53 activity as well as key proteins involved in cell cycle control, DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34885154
DOI: 10.3390/cancers13236042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPM1D Is a Therapeutic Target in Childhood Neural TumorsPMID 34885154Read ↗

PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumorsSemantic proximity Read ↗

WIP1 phosphatase as a potential therapeutic target in neuroblastoma.Semantic proximity Read ↗

Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1DSemantic proximity Read ↗

The role of PPM1D in cancer and advances in studies of its inhibitorsSemantic proximity Read ↗

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.Semantic proximity Read ↗

PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas.Semantic proximity Read ↗

PPM1D/Wip1 is amplified, overexpressed, and mutated in human Non-Hodgkin LymphomasSemantic proximity Read ↗

Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.Semantic proximity Read ↗

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.Semantic proximity Read ↗

Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progressionSemantic proximity Read ↗

Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progressionSemantic proximity Read ↗

PPM1D, a Promising Therapeutic Target Uncovered Through shRNA Library Screening, Plays a Pivotal Role in Regulating the Progression of Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.